RxDoctor Payments DataLook up a doctor →

William Garvey

Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1114947769

Payments from drug & device makers

$3,793,097in general payments, 2019–2025

Across 3,680 payments — averaging $1030.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$3M
  • Eli Lilly$330K
  • Novo Nordisk$137K
  • F. Hoffmann-la Roche AG$54K
  • Boehringer Ingelheim$53K
  • Genentech, Inc.$40K
  • plus $145K from 23 others
$30,148in research payments, 2019–2025

Across 22 payments — averaging $1370.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$27K
  • Novo Nordisk AS$3K
  • Eli Lilly$644

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,793,097 in reported general payments places this provider in the 95th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

See all endocrinology, diabetes & metabolism providers in Alabama

Other endocrinology, diabetes & metabolism in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →